A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

Inclusion Criteria:

• Ocular Surface Disease Index (OSDI) score of ≥ 28 and ≤ 65 (based upon a 0 to 100scale) at Screening. (Day -7) and an OSDI score of ≥ 18 and ≤ 65 (based upon a 0 to 100 scale) at Baseline (Day 1).

• Three consecutive tear breakup time (TBUT) tests of ≤ 10 seconds in at least 1 eyeat both the Screening (Day -7) and Baseline (Day 1) Visits.

• Grade 1 to 4 (modified National Eye Institute [NEI] Grid, score range = 0 to 5)staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areasexamined) that is related to dry eye in at least 1 eye at both Screening (Day -7)and Baseline (Day 1).

• Have used an artificial tear product for dry eye disease (DED) within 6 months ofScreening (Day -7) Visit.

Exclusion Criteria:

• Participant has uncontrolled severe systemic disease that, in the assessment of theinvestigator, would put safety of the subject at risk through participation, orwhich would prevent or confound protocol-specified assessments (e.g., hypertensionand diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupuserythematosus, immunodeficiency disease, etc.).

• Participant has worn contact lenses in the last 90 days prior to the Screening (Day -7) Visit and/or participant anticipates contact lens wear during the study.

• Any scheduled or planned systemic surgery or procedure during the study, which inthe investigator's opinion, may impact the participant's study participation.